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Background
With the advent of combined antiretroviral therapy
(cART) in 1996 and the decreased incidence of AIDS and
death, growing concerns about cancer and in particular
non-AIDS-defining cancers have emerged. For instance, in
a mortality study conducted in France in 2005, AIDS
malignancies including Non-Hodgkin lymphomas
(NHL), Kaposi sarcoma and cervical cancer still repre-
sented 14 percent of the causes of death among HIV-
infected persons and the part of non-AIDS-defining can-
cers rose from 13 percent in 2000 to 21 percent in 2005.
ONCOVIH is a cross-sectional study based on the pro-
spective reporting of new cases of malignant tumors
occurring in patients with HIV infection, observed in
France, during a 12-month period, year 2006.
Methods
The main objectives of ONCOVIH were:
• to prospectively record all the new cases of malignancies
in HIV-infected patients in 2006 in France;
• to describe the main characteristics of HIV infection
(CD4 cell count and nadir, history of antiretroviral ther-
apy, plasma HIV-RNA, AIDS stage), cancer (personal and
family history of cancer, viral co-infections, histology and
staging of the tumor), and of therapeutic management of
the cancer; and
• to evaluate the prognosis of HIV-infected patients with
malignancies.
The data were collected from more than 300 different care
centers involved in the management of patients with
either HIV or malignancies. Duplicate records of the same
patient from different centers were reconciled for the HIV-
and tumor-associated data. Clinical follow-up, antiretro-
viral therapy and characteristics of HIV infection, thera-
peutic cancer management including chemotherapy,
radiotherapy, or immunotherapy and occurrence of death
and cause of death were collected every three months dur-
ing the first year following the diagnosis. Centralized
review of diagnoses and classification of the cause of
death were done by a team of clinicians and epidemiolo-
gists. Data from HIV patients in care in 2006 in France
were extracted from the French Hospital database on HIV
(ANRS CO4 FHDH).
Results
In the ONCOVIH study, 694 tumors were reported in 690
patients by 116 clinical centers for an estimated 83,000
HIV infected patients in care. Of those, the case report
forms were completed for 673 tumors in 669 patients.
Most common cancers were NHL (21.5%, n = 145),
Kaposi sarcoma (15.9%, n = 107), lung cancer (9.4%, n =
63), anal cancer (8.2%, n = 55), Hodgkin lymphoma
(7.6%, n = 51), cutaneous non-melanoma (5.8%, n = 49)
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and liver cancers (5.6%, n = 38). Cervix cancer was diag-
nosed in 10 women. For AIDS and non-AIDS-defining
cancers, median ages at diagnosis were 44 years (IQR =
38–51) and 49 years (IQR = 42–57). Twenty percent and
21% of diagnosed patients were women. For AIDS-defin-
ing cancers, the median CD4 cell count at the time of can-
cer was 194/mm3 (IQR = 67–359) and the nadir CD4 cell
count was 135/mm3 (IQR = 47–263). For non-AIDS-
defining cancers, the corresponding figures were 330/
mm3 (IQR = 192–503) and 147/mm3 (IQR = 51–258).
The diagnosis of cancer revealed HIV infection in 28 per-
cent and 5 percent of cases. Twenty-three percent and 62
percent were receiving cART and had plasma HIV-
RNA<500 copies/ml, respectively. In FHDH at the same
period, the median age of HIV patients in care was 43
years (IQR = 37–49) with 33% women. The median CD4
cell count was 454 (IQR = 312–634), and 67 percent
received cART with plasma HIV-RNA<500 copies/ml. In
the general population, the mean age at diagnosis of can-
cer was 66 years of age in 2005.
The overall 1-year survival rate was 72% (n = 185, 95% CI:
68–75%). Prognosis after a diagnosis of lung cancer (1-
year survival rate: 35%) hepatocarcinoma (47%) and
NHL (65%) were the worst. Most common causes of
death were NHL (45), lung cancer (35) and liver diseases
(hepatocarcinoma or cirrhosis or hepatic failure, n = 18).
Conclusion
NHL and Kaposi sarcoma remain the most frequent can-
cers diagnosed in 2006 in France in HIV-infected people
despite the widespread use of cART. However, non-AIDS-
defining cancers including lung cancer, anal cancer and
Hodgkin lymphoma represent 62% of diagnosed cancers.
Diagnosis of cancer occurred at much younger age than in
the general population, in patients with a lower CD4 cell
count and more often with detectable plasma HIV RNA
than in HIV-infected patients not diagnosed with cancer,
suggesting that a better control of HIV and its induced
immunodeficiency is required to prevent AIDS and non-
AIDS cancer in HIV infected patients in addition to the
control of other usual risk factors for cancer.Page 2 of 2
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